Short Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Decreases By 12.0%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 4,600,000 shares, a decline of 12.0% from the September 15th total of 5,230,000 shares. Based on an average daily volume of 389,800 shares, the days-to-cover ratio is currently 11.8 days. Approximately 18.6% of the company’s shares are short sold.

Arcturus Therapeutics Trading Down 2.5 %

Shares of ARCT opened at $20.92 on Tuesday. The stock has a market capitalization of $563.42 million, a P/E ratio of -5.35 and a beta of 2.61. The firm’s fifty day simple moving average is $20.99 and its two-hundred day simple moving average is $25.66. Arcturus Therapeutics has a 12 month low of $17.52 and a 12 month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The firm had revenue of $49.86 million for the quarter, compared to analyst estimates of $21.00 million. During the same quarter in the prior year, the business earned ($1.98) earnings per share. As a group, research analysts predict that Arcturus Therapeutics will post -2.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a research note on Monday, August 12th. They issued an “outperform” rating and a $70.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Finally, Leerink Partnrs raised shares of Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Arcturus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $71.40.

Hedge Funds Weigh In On Arcturus Therapeutics

Several institutional investors have recently made changes to their positions in ARCT. Wellington Management Group LLP raised its holdings in shares of Arcturus Therapeutics by 40.3% during the fourth quarter. Wellington Management Group LLP now owns 60,841 shares of the biotechnology company’s stock valued at $1,918,000 after purchasing an additional 17,491 shares during the period. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Arcturus Therapeutics by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock valued at $1,078,000 after purchasing an additional 778 shares during the period. Denali Advisors LLC acquired a new stake in shares of Arcturus Therapeutics in the 1st quarter worth about $209,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Arcturus Therapeutics by 66.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,153 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 2,064 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Arcturus Therapeutics by 148.0% in the 1st quarter. Principal Financial Group Inc. now owns 17,516 shares of the biotechnology company’s stock worth $592,000 after acquiring an additional 10,454 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.